1 Perfluoroisobutene, a pyrolysis product of polytetra fluoroethene may cause pulmonary oedema and death when inhaled. Oral N-acetylcysteine has shown protection against inhalation of perfluoroisobutene and in this study we have tried to elucidate the mechanism by which protection is mediated.
2 Protection against the lethal effects of inhaled per fluoroisobutene has been shown when N-acetylcys teine has been orally administered 4, 6 or 8 h before gas exposure.
3 Plasma levels of cysteine, glutathione and N-acetylcys teine were increased for up to 7 h following oral administration of Nac.
4 N-acetylcysteine was not detected in the bronchio alveolar lavage fluid following oral administration.
5 Duration of protection in vivo has been related to the duration of increased thiol levels in the plasma.
Webb WRClinical evaluation of a new effective mucolytic agent (N-acetylcysteine) . American Review Respiratory Diseases1962 ; 86: 115-6.
2.
Chodosh S.Acetylcysteine in chronic bronchitis. European Journal of Respiratory Diseases1980; 61: supp 111: 90-2.
3.
Ziment I.Acetylcysteine: a drug with an interesting past and a fascinating future. Respiration1986; 50: 26-30.
4.
Prescott LF, Critchley Jajh.The treatment of acetaminophen poisoning. Annual Review of Pharmacology and Toxicology1983; 23: 87-101.
5.
Ziment I.Acetylcysteine: a drug that is much more than a mucokinetic. Biomed-Pharmacotherapy1988; 42: 513-20.
6.
Moldeus P., Cotgreave IA, Berggren M.Lung Protection by a Thiol-Containing Antioxidant: N-acetylcysteine . Respiration1986; 50: (1) 31-42.
7.
Unverferth DV et al. The efficacy of Nac in preventing doxorubicin induced cardiomyopathy in dogs. Seminars in Oncology1983a; 10: 2-6.
8.
Unverferth DV , et al. N-acetylcysteine prevents the doxorubicin induced decrease of cyclic GMP. Seminars in Oncology1983b; 10: 49-52.
9.
Morgan LR, Donley PJ, Harrison EF, Hunter HLProtective effect of N-acetylcysteine on the urotoxicity produced by oxazaphosphosine without interference with anticancer activity. European Journal of Cancer and Clinical Oncology1982; 18: 113-4.
10.
Lailey AF et al. Protection by cysteine esters against chemically induced pulmonary oedema. Biochemical Pharmacology1991; 42: Supp: S47-S54.
11.
Velury S., Howell S.B.Measurement of plasma thiols after derivatization with monobromobimane . Journal of Chromatography1988; 424: 141-6.
12.
Sciuto AM, Strickland PT, Kennedy TP, Gurtner GHProtective Effects of Nac Treatment after Phosgene Exposure in Rabbits . American Journal of Respiratory Critical Care Medicine1995 ; 151: 768-72.
13.
Johnston RE , Hawkins HC, Weikel JHThe Toxicity of N-acetylcysteine in Laboratory Animals. Seminars in Oncology1983; 10: (1) 17-25.
Olsson B., Johansson M., Gabrielsson J., Bolme P.Pharmacokinetics and Bioavailability of Reduced and Oxidized N-acetylcysteine . European Journal of Clinical Pharmacology1988; 34: 77-82.
16.
Sheffner AL et al. Metabolic Studies with Acetylcysteine . Biochemical Pharmacology1966; 15: 1523-35.
17.
Bonanomi L. , Gazzaniga A.Toxicological, Pharmacokinetic and Metabolic Studies on Acetylcysteine. European Journal Respiratory Diseases1980; 61: Supp 111: 45-51.
18.
Borgstrom L. , Kagedal B.Dose Dependent Pharmacokinetics of Nac after Oral Dosing to Man. Biopharmaceutics and Drug Disposition1990; 11: 131-6.
19.
Burgunder JM , Varriale A., Lauterburg BHEffect of Nac on plasma cysteine and glutathione following paracetamol administration. European Journal of Clinical Pharmacology1989; 36: 127-131.
20.
Hultberg B. et al. Plasma Homocysteine and thiol Compound Fractions after Oral Administration of N-acetylcysteine. Scandinavian Journal Clinical Laboratory Investigations1994 ; 54: 417-22.
21.
Dinsdale D. , Green JA, Manson MM, Lee MJThe ultrastructural immunolocalization of τ-glutamyltranspeptidase in rat lung: correlation with the histochemical demonstration of enzyme activity . Histochemical Journal1992; 24: 144-52.
22.
Deneke SM et al. Mechanisms of use of Extracellular Glutathione by lung epithelial cells and pulmonary artery endothelial cells. American Journal Respiratory Cellular MolecularBiology1995; 12: 662-8.
23.
Meyer A., Buhl R., Kampf S., Magnussen H.Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. American Journal of Respiratory and Critical Care Medicine1995; 152: (3) 1055-60.
24.
Cotgreave IA , Eklund A., Larrson K., Moldeus PWNo Penetration of Orally administered N-acetylcysteine into Bronchoalveolar Lavage Fluid . European Journal Respiratory Diseases1987 ; 70: 73-7.
25.
Bridgeman Mme et al. Effect of N-acetylcysteine on the Concentrations of Thiols in Plasma, Bronchoalveolar Lavage Fluid, and Lung Tissue. Thorax1994; 49: 670-5.
26.
Cantin AM, North SL, Hubbard RC, Crystal RCNormal alveolar epithelial lining fluid contains high levels of glutathione . Journal of Applied Physiology1987; 63: (1) 152-7.
